Who We Are
Our Mission
AnHorn Medicines is a novel drug discovery company with a strong pipeline, offering therapies that target and degrade disease-related proteins. Our mission is to develop new class of drugs BIGPRO® (Bi-functional liGand induced PROteolysis) under the foundation of Targeted Protein Degradation (TPD), to address a broad range of life-threatening and life-impairing diseases.
We focus on novel therapies for cancer, neurodegeneration, and aging diseases. We are turning innovation into new therapeutics – new opportunities to target difficult-to-treat diseases and diseases plagued by drug resistance.
Our proprietary BIGPRO® protein degrader gives precise elimination of diseased protein that helps the human body to return to a healthy state.
Our founder Dr. CC Lin and his team have built on groundbreaking AIMCADD® platform (Auto-bio-Informatic-MedChem-Computer-Aid Drug Design), which is a knowledge base of drug discovery expertise that generates successful candidates with efficiency. Our mission is to unlock the full potential of BIGPRO® protein degradation by developing our robust pipeline and by partnering with the world’s leading drug development companies.
Our Strategies
• Develop extensive BIGPRO® pipeline at early drug development stages.
• Identify novel E3 ligases with effective binder.
• Extending the portfolio to the rest 80% novel targets for treatments of cancer, neurodegenerative, and age-related diseases.
• Establishing an extensive and multi-layered patent portfolio to protect our technologies and product candidates.